Abstract
With the plethora of receptor targets evolving as the result of nicotinic acetylcholine receptor (nAChR) cloning it is possible that new molecular entities selective for subtypes of nAChRs can be developed which are potentially free of the side effect liabilities associated with (-)-nicotine. Recent data also suggests that neuronal nAChR function can be enhanced at sites distinct from where (-)-nicotine interacts on the a subunit. nAChR agonists whose actions may occur via the selective interaction with central nAChRs subtypes, and allosteric modulators that indirectly affect ligand-gated nAChR function encompass a broader class of compounds which can be termed cholinergic channel activators (ChCAs). Functionally, ChCAs may enhance central neuronal nAChR mediated transmission while substantially reducing the side-effect liabilities normally associated with (-)-nicotine. ChCAs lacking cardiovascular or other CNS side effects associated with (-)-nicotine may thus represent a potential novel therapeutic approach to ameliorate many of the CNS deficits accompanying AD or other related disorders. ABT 418 [(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole hydrochloride] is a selective prototypic ChCA currently in development for the treatment of AD (see accompanying abstracts). ABT-418 may be a safe and effective ChCA for the potential treatment of the cognitive and emotional impairments associated with AD. The therapeutic potential of ChCAs for neuroprotection, smoking cessation, anxiety disorders, schizophrenia, attentional deficit disorder, Touretté s syndrome, analgesia and depression will be reviewed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReference
Garvey, D.S., Wasicak, J. T., Decker, M. W., Brioni, J. D., Buckley, M. J., Sullivan, J. P., Carrera, G. M., Holladay, M. W., Americ, S. P., Williams, M. “Novel Isoxazoles Which Interact with Brain Cholinergie Channel Receptors Have Intrinsic Cognitive Enhancing and Anxiolytic Activities,” J. Med.Chem. 1994 in press
Americ, S. P., Sullivan, J. P., Briggs, C. A., Donnelly-Roberts, D, Anderson, D, Raskiewicz, J., Hughes, M., Cadman, E., Adams, P., Garvey, D., Wasicak, J., Williams, M. “ABT 418: A Novel Cholinergic Ligand With Cognition Enhancing and Anxiolytic Activities: I. In Vitro Characterization,” . J.PharmacolExp. Therap. 1994 in press
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Basel AG
About this chapter
Cite this chapter
Arneric, S.P. et al. (1994). ABT — 418, a Novel Nicotinic Agonist. In: Clarke, P.B.S., Quik, M., Thurau, K., Adlkofer, F. (eds) International Symposium on Nicotine: The Effects of Nicotine on Biological Systems II. Experientia Supplementum, vol 71. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7416-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-0348-7416-8_10
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-7643-5087-1
Online ISBN: 978-3-0348-7416-8
eBook Packages: Springer Book Archive